FDA Oncology Announcements

Multikinase inhibitor × Other × Clear all

5 Announcements

Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US

Drugs: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody, LENVIMA (lenvatinib) · Multikinase inhibitor

Lenvatinib in combination with Everolimus

Drugs: Lenvima (lenvatinib) · Multikinase inhibitor, everolimus · MTOR inhibitor

Lenvatinib (Lenvima)

Drug: Lenvima (lenvatinib) · Multikinase inhibitor

Regorafenib

Drug: Stivarga tablets (regorafenib) · Multikinase inhibitor

Vandetanib

Drug: Vandetanib Tablets (vandetanib) · Multikinase inhibitor